PrEP with tenofovir/emtricitabine for HIV prevention proves safe during pregnancy

In a single-site South African RCT, pregnant women who took daily tenofovir disoproxil fumarate (300 mg) with emtricitabine (200 mg) for PrEP at a median of 19 weeks' gestation vs. waiting until cessation of breast feeding were not at excess risk for preterm labor or low birth weight. Study authors conclude that these findings support the use of tenofovir disoproxil fumarate and emtricitabine in pregnancy and can be used to allay safety concerns among pregnant women.